Cabaletta Bio Inc. (CABA) Prepares for Rese-Cel Launch in Autoimmune Disease Market
Cabaletta Bio Inc. is gearing up for a pivotal moment with its Rese-Cel product aimed at treating autoimmune diseases, marking a potential growth opportunity.
Editorial Staff 8 days ago